false
Catalog
Initiating Buprenorphine for Patients Using Fentan ...
Slides
Slides
Back to course
Pdf Summary
This document is a collection of slides and references on the topic of initiating buprenorphine for patients using fentanyl. The slides cover various aspects of buprenorphine initiation, including different dosing strategies, medication options, and supportive medications. The references provide additional information and research studies on the topic.<br /><br />The slides discuss the importance of initiating buprenorphine for patients using fentanyl, as fentanyl has become a major driver of drug overdose deaths in recent years. They also highlight the benefits of medication-assisted treatment (MAT), including decreased mortality and increased treatment retention and decreased illicit opioid use.<br /><br />Different dosing strategies for buprenorphine initiation are presented, including the classic initiation method, high-dose starts, low-dose starts, and controlled environment starts. The slides provide step-by-step instructions for each method and discuss the advantages and considerations of each approach.<br /><br />Supportive medications for managing withdrawal symptoms and providing analgesia during buprenorphine initiation are also discussed. These medications include clonidine, ondansetron, hydroxyzine, ibuprofen, and loperamide.<br /><br />The references provide additional information and research studies on topics such as microdosing of buprenorphine, transitioning from methadone to buprenorphine, and the use of the medication-first model in opioid use disorder treatment.<br /><br />Overall, this document provides a comprehensive overview of buprenorphine initiation strategies and supporting evidence for clinicians working with patients using fentanyl.
Keywords
buprenorphine initiation
patients using fentanyl
dosing strategies
medication options
supportive medications
medication-assisted treatment
MAT
withdrawal symptoms
analgesia
opioid use disorder treatment
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.
Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 and grant no. 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
PCSS-MOUD
PCSS-MOUD.org
pcss@aaap.org
8-Hour DEA Training Inquiries, email
PCSS-MOUD
.
ORN
opioidresponsenetwork.org
×
Please select your language
1
English